ATS is undergoing a significant portfolio transformation, exiting transportation and restructuring operations, which creates near-term earnings noise but targets 50-75bps margin expansion in FY2027. The 18.4% bookings decline and 8.5% backlog contraction signal demand softness, particularly in life sciences, that may pressure revenue visibility. Watch Q1 FY2027 revenue guidance of $700M-$740M and monitor whether margin improvement materializes as restructuring costs phase down.
How the stock moved after the report
NEUTRAL VIEWSTOCK BELOW ENTRY AT T+60- T+0 · May 28 $30.43entry
- T+1 · 6mo ago +1.61%α +1.37% · $30.92
- T+5 · 6mo ago −5.19%α −5.14% · $28.85
- T+20 · 5mo ago −7.95%α −4.81% · $28.01
- T+60 · 3mo ago −35.13%α −36.86% · $19.74
Price Chart
REPLAYWatch the reaction play outHow similar events traded
Executive Summary
ATS reported Q4 FY2026 results with adjusted revenues of $744.3M (+3.2% YoY) and adjusted EBITDA of $102.5M (+5.6% YoY), but adjusted EPS declined 12.2% to $0.36. The company is executing a major restructuring of its transportation business, incurring $28.3M in reorganization costs and closing facilities, while guiding for modest FY2027 revenue growth and 50-75bps margin expansion. Order bookings fell 18.4% YoY to $704M and backlog declined 8.5% to $1.958B, signaling demand headwinds.
Key Facts
- Q4 adjusted revenues $744.3M, +3.2% YoY; organic revenue growth was only 1.5%
- Q4 adjusted EPS $0.36, -12.2% YoY from $0.41
- Q4 adjusted EBITDA $102.5M, +5.6% YoY; adjusted EBITDA margin improved 31bps to 13.8%
- Q4 net loss of $16.2M improved from -$68.9M a year ago, driven by $146.9M prior-year EV customer settlement
- Order bookings $704M, -18.4% YoY; organic bookings declined 19.3%
- Order backlog $1,958M, -8.5% YoY; life sciences backlog down 10.2% to $1,077M
- Transportation revenues collapsed 61.1% YoY to $26.6M; segment being restructured and will cease to be reported separately
- Restructuring charges of $15.2M in Q4; $28.3M in transportation reorganization costs; $9.8M in services reorganization costs
- Net debt reduced to $1,151.2M from $1,474.5M; leverage ratio improved to 2.8x from 3.9x
- Free cash flow of $124.1M in Q4, up from $10.3M a year ago
- FY2027 guidance: Q1 revenues $700M-$740M; modest full-year revenue growth; adjusted operating margin expected to improve 50-75bps
- Transportation reorganization expected to remove ~$50M in dilutive revenues in FY2027
Financial Impact
Q4 adjusted revenues $744.3M (+3.2% YoY), adjusted EPS $0.36 (-12.2% YoY), adjusted EBITDA $102.5M (+5.6% YoY). FY2026 full-year adjusted revenues $2,970.1M (+10.8% YoY), adjusted EPS $1.69 (+15.0% YoY).
Risk Factors
- Order bookings declining 18.4% YoY with organic bookings down 19.3% signals weakening demand pipeline
- Life sciences revenue fell 9.3% YoY and backlog dropped 10.2%, the company's largest end market
- Transportation restructuring carries execution risk; $28.3M in reorganization costs already booked with more expected
- Tariff exposure: ~20% of adjusted revenues from Canadian/European operations sold into the U.S. face potential tariff impacts
- Adjusted EPS declining 12.2% YoY despite revenue growth indicates margin pressure from restructuring costs
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 5 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 6-K Filing (Primary) | 0001394832-26-000017 |
| Document: form6k-fy26q4.htm | 0001394832-26-000017 |
| Document: 0001394832-26-000017-index-headers.html | 0001394832-26-000017 |
| Document: 0001394832-26-000017-index.html | 0001394832-26-000017 |
| Document: 0001394832-26-000017.txt | 0001394832-26-000017 |
Track record
13 reports on ATS
2 of 3 bullish or bearish reports moved the stock their way by T+5. Best: +10.42% at T+60 after the Aug 6, 2026 report. 3 of 3 went positive at some point.
Filters
- Nov 6, 202610d ago Institutional Cluster Neutral 3/10 Entry $16.97 to $17.50 Now $17.96 +5.83% ▲ +3.12% +0.53% vs SPY
- Nov 4, 202612d ago 6-K Bearish 6/10 Entry $17.57 to $17.65 Now $17.96 −2.22% ▼ −0.46% −1.37% vs SPY
- Oct 30, 202617d ago 6-K Neutral 2/10 Entry $18.97 to $17.74 Now $17.96 −5.32% ▼ −6.48% −6.56% vs SPY
- Sep 3, 202610w ago 6-K Neutral 2/10 Entry $19.57 to $19.20 Now $17.96 −8.23% ▼ −1.89% −0.74% vs SPY
- Aug 9, 202614w ago Institutional Cluster Bearish 5/10 Entry $19.73 to $19.59 Now $17.96 +8.97% ▲ +0.71% +0.66% vs SPY
- Aug 7, 202614w ago 6-K Neutral 2/10 Entry $21.13 to $20.31 Now $17.96 −15.00% ▼ −3.88% −4.28% vs SPY
- Aug 6, 202614w ago 6-K Bearish 7/10 Entry $20.53 to $20.13 Now $17.96 +12.52% ▲ +1.95% +3.16% vs SPY
- Jul 27, 202616w ago 6-K Neutral 2/10 Entry $26.59 to $27.24 Now $17.96 −32.46% ▲ +2.44% +1.37% vs SPY
- Jul 2, 202619w ago 6-K Neutral 2/10 Entry $27.68 to $27.74 Now $17.96 −35.12% ▲ +0.22% −0.71% vs SPY
- Jun 11, 202622w ago 6-K Neutral 2/10 Entry $26.88 to $28.32 Now $17.96 −33.18% ▲ +5.36% +4.92% vs SPY
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers